Analysis: Merck's statins turn up more muscle side effects than their rivals

Statins have long come with safety worries, but a new analysis shows that Merck & Co.'s ($MRK) products may carry more than their brethren. Pacing side effects data, Advera Health Analytics found that muscle-related side effects--which are commonly linked to the drugs--show up more often in the New Jersey giant's Zocor, Mevacor and Vytorin than in drugs in the rest of the class. More from FiercePharma

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

To take on AbbVie’s megablockbuster Humira, drugmakers need compelling data for physicians. Could Eli Lilly's Taltz be up to the challenge?

Why did GSK tweak its strict ethics measures for sales reps? When it first nixed incentive-based compensation, it thought other pharmas would, too.